Ocugen, Inc. announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO). Dr. Qamar is a distinguished healthcare professional with a rich background in clinical research, having contributed her expertise to esteemed Ivy League institutions including Yale University, Harvard University, and University of Pennsylvania. Her expertise encompasses the development of Phase I-IV clinical protocols and execution of clinical studies, FDA inspections, and effective leadership of medical affairs teams. Dr. Qamar has expertise in multiple therapeutic areas, including gene and cell therapy, vaccines, oncology (Heme-Onc, CAR-T, rare tumors, sarcoma, melanoma, women's health, GU & GI, fetal oncology), rheumatology, dermatology, neurology, cardiology, hepatology, and infectious diseases.

Prior to joining Ocugen, Dr. Qamar was Senior Vice President, Head of R&D at FSD Pharma?demonstrating her commitment to advancing scientific innovation and pharmaceutical development.